FATE logo

Fate Therapeutics (FATE) Company Overview

Profile

Full Name:

Fate Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 1, 2013

Indexes:

Not included

Website:

http://www.fatetherapeutics.com

Description:

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmable cellular immunotherapies for the treatment of cancer and immune disorders. The corporation was registered in the state of Delaware in 2007, with headquarters in San Diego, California. The company is developing programmable cellular immunotherapeutic agents for the treatment of oncological diseases and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapy based on engineered induced pluripotent cells, and immune regulation programs, including immunotherapy with hematopoietic cells to protect the immune system of patients who have undergone hematopoietic cell transplantation, and to suppress autoimmune reactions.

Key Details

Price

$1.04

Market Cap

$119.02 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$63.53 M(-34.03% YoY)

Annual EPS

-$1.64(+43.64% YoY)

PE Ratio

-

Annual ROE

-37.76%

Annual Debt To Equity

0.00

Beta

2.29

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 19, 24 Needham
Hold
Nov 13, 24 Needham
Hold
Aug 22, 24 HC Wainwright & Co.
Neutral
Aug 14, 24 Needham
Hold
Jun 17, 24 Piper Sandler
Overweight
May 16, 24 HC Wainwright & Co.
Neutral
May 10, 24 Wedbush
Neutral
May 10, 24 Piper Sandler
Neutral
May 10, 24 Canaccord Genuity
Buy
May 10, 24 BMO Capital
Market Perform

Screeners with FATE included

Growing Shares Outstanding
US stocks
Stocks with high beta
Stocks recommended to hold
Stocks below SMA 200
Biggest stock losers today
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$1.04
FATE price is $1.04

Price All-time High

$117.40
FATE price is currently -99.11% below its historical high of $117.40

Price Analysts Target

$5.00
FATE price is currently -79.10% lower than the consensus analysts' forecast

Price Today Change

-6.7%
FATE price is down -6.7% today

Price YTD Change

-36.28%
FATE price is down -36.28% since January 1st

Price 3-Year Change

-96.84%
FATE price is down -96.84% over the past 3 years

Market cap

Market Cap

$119.02 M
FATE market capitalization is $119.02 million

Market Cap 3-Year Change

-96.27%
FATE market capitalization is down -96.27% over the past 3 years

Market Cap All-time High

$10.90 B
FATE market capitalization is currently -98.91% below its historical high of $10.90 billion

Market Cap Sector Rank

48.36%
FATE market capitalization is higher than 48.36% of companies in Healthcare sector

Technical

Beta

2.29
FATE beta is 2.29

200-day SMA

$2.93
FATE price is currently -64.36% below its 200-day simple moving average

14-day RSI

38.12
FATE 14-day relative strength index is 38.12

30-day Relative Volume

1.14
FATE 30-day relative volume is 1.14

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$63.53 M
FATE annual revenue is $63.53 million

Annual Revenue Analysts Estimate

$13.60 M
FATE annual revenue is currently +367.11% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

-34.03%
FATE annual revenue is down -34.03% year-on-year

Annual Revenue Sector Rank

50.67%
FATE annual revenue is higher than 50.67% of companies in Healthcare sector

Profit

Annual Gross Profit

-
FATE annual gross profit value is unknown

Annual Gross Margin

-
FATE annual gross profit margin value is unknown

Annual Operating Profit

-$190.51 M
FATE annual operating income is -$190.51 million

Annual Operating Margin

-299.86%
FATE annual operating profit margin is -299.86%

Annual Net Income

-$160.93 M
FATE annual net profit is -$160.93 million

Annual Net Margin

-253.30%
FATE annual net profit margin is -253.30%

EPS

Annual EPS

-$1.64
FATE annual earnings per share is -$1.64

Annual EPS Analysts Estimate

-$1.59
FATE annual earnings per share is currently +3.03% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+43.64%
FATE annual earnings per share is up +43.64% year-on-year

Annual EPS Sector Rank

47.65%
FATE annual earnings per share is higher than 47.65% of companies in Healthcare sector

ROA & ROE

Annual ROA

-26.56%
FATE annual return on assets is -26.56%

Annual ROE

-37.76%
FATE annual return on equity is -37.76%

EBIT & EBITDA

Annual EBIT

-$190.51 M
FATE annual earnings before interest & taxes is -$190.51 million

Annual EBITDA

-$172.23 M
FATE annual EBITDA is -$172.23 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
FATE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
FATE price to earnings ratio is unknown

PB Ratio

PB Ratio

0.33
FATE price to book ratio is 0.33

PB Ratio Sector Rank

22.42%
FATE price to book ratio is higher than 22.42% of companies in Healthcare sector

PS Ratio

PS Ratio

8.85
FATE price to sales ratio is 8.85

PS Ratio Sector Rank

74.87%
FATE price to sales ratio is higher than 74.87% of companies in Healthcare sector

Enterprise value

Enterprise Value

$180.09 M
FATE enterprise value is $180.09 million

Enterprise Value Sector Rank

55.87%
FATE enterprise value is higher than 55.87% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.01
FATE EV/EBITDA is -1.01

EV/EBITDA Sector Rank

45.25%
FATE EV/EBITDA is higher than 45.25% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

8.48
FATE annual current ratio is 8.48

Annual Quick Ratio

-
FATE annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
FATE annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
FATE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
FATE piotroski f-score value is unknown

Altman Z-Score

-3.26
FATE altman z-score is -3.26

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$506.22 M
FATE annual total assets is $506.22 million

Annual Non Current Assets

$174.68 M
FATE annual long term assets is $174.68 million

Annual Current Assets

$331.54 M
FATE annual total current assets is $331.54 million

Annual Cash & Cash Equivalents

$41.87 M
FATE annual cash & cash equivalents is $41.87 million

Equity

Annual Book Value

$368.41 M
FATE annual book value is $368.41 million

Annual Working Capital

$292.45 M
FATE annual working capital is $292.45 million

Liabilities

Annual Total Liabilities

$137.80 M
FATE annual total liabilities is $137.80 million

Annual Total Long Term Liabilities

$98.71 M
FATE annual total long term liabilities is $98.71 million

Annual Current Liabilities

$39.09 M
FATE annual total current liabilities is $39.09 million

Annual Accounts Payable

$4.72 M
FATE annual accounts payable is $4.72 million

Debt

Annual Total Debt

$103.54 M
FATE annual total debt is $103.54 million

Annual Total Debt 1-Year Change

-5.31%
FATE annual total debt is down -5.31% year-on-year

Annual Long Term Debt

$97.36 M
FATE annual long term debt is $97.36 million

Annual Short Term Debt

$6.18 M
FATE annual short term debt is $6.18 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$254.04 M
FATE annual total expenses is $254.04 million

Annual Operating Expenses

$254.04 M
FATE annual total operating expenses is $254.04 million

Annual Cost Of Goods Sold

-
FATE annual cost of goods sold value is unknown

Annual SGA

$81.45 M
FATE annual SGA is $81.45 million

Annual D&A

$18.28 M
FATE annual depreciation & amortization is $18.28 million

Annual Interest Expense

-
FATE annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$132.26 M
FATE annual cash flow from operations is -$132.26 million

Annual CFO 1-Year Change

+46.71%
FATE annual cash flow from operations is up +46.71% year-on-year

Annual CFI

$112.67 M
FATE annual cash flow from investing activities is $112.67 million

Annual CFI 1-Year Change

-32.44%
FATE annual cash flow from investing activities is down -32.44% year-on-year

Annual CFF

$85.00 K
FATE annual cash flow from financing activities is $85.00 thousand

Annual CFF 1-Year Change

-99.08%
FATE annual cash flow from financing activities is down -99.08% year-on-year

Free CashFlow

Annual FCF

-$138.42 M
FATE annual free cash flow is -$138.42 million

Annual FCF 1-Year Change

+51.22%
FATE annual free cash flow is up +51.22% year-on-year

CAPEX

Annual CAPEX

$6.15 M
FATE annual capital expenditures is $6.15 million

Annual CAPEX 1-Year Change

-82.7%
FATE annual capital expenditures is down -82.7% year-on-year

Institutional Ownership

Similar stocks

CLLS logo
Cellectis SA (CLLS)
Sagimet Biosciences (SGMT)
TSVT logo
2seventy bio (TSVT)
TIL logo
Instil Bio (TIL)
RPID logo
Rapid Micro Biosystems (RPID)
MCRB logo
Seres Therapeutics (MCRB)
SEER logo
Seer (SEER)
CHRS logo
Coherus BioSciences (CHRS)
STRO logo
Sutro Biopharma (STRO)

FAQ

  • What is the ticker symbol for Fate Therapeutics?
  • Does Fate Therapeutics pay dividends?
  • What sector is Fate Therapeutics in?
  • What industry is Fate Therapeutics in?
  • What country is Fate Therapeutics based in?
  • When did Fate Therapeutics go public?
  • Is Fate Therapeutics in the S&P 500?
  • Is Fate Therapeutics in the NASDAQ 100?
  • Is Fate Therapeutics in the Dow Jones?
  • When was Fate Therapeutics's last earnings report?
  • When does Fate Therapeutics report earnings?
  • Should I buy Fate Therapeutics stock now?

What is the ticker symbol for Fate Therapeutics?

The ticker symbol for Fate Therapeutics is NASDAQ:FATE

Does Fate Therapeutics pay dividends?

No, Fate Therapeutics does not pay dividends

What sector is Fate Therapeutics in?

Fate Therapeutics is in the Healthcare sector

What industry is Fate Therapeutics in?

Fate Therapeutics is in the Biotechnology industry

What country is Fate Therapeutics based in?

Fate Therapeutics is headquartered in United States

When did Fate Therapeutics go public?

Fate Therapeutics's initial public offering (IPO) was on October 1, 2013

Is Fate Therapeutics in the S&P 500?

No, Fate Therapeutics is not included in the S&P 500 index

Is Fate Therapeutics in the NASDAQ 100?

No, Fate Therapeutics is not included in the NASDAQ 100 index

Is Fate Therapeutics in the Dow Jones?

No, Fate Therapeutics is not included in the Dow Jones index

When was Fate Therapeutics's last earnings report?

Fate Therapeutics's most recent earnings report was on Nov 12, 2024

When does Fate Therapeutics report earnings?

The next expected earnings date for Fate Therapeutics is May 9, 2025

Should I buy Fate Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions